Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 4/20 | 0.33 |
| ▸ | DRD5 | P21918 | 4/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284241 | 0.90 | PDE10A (0.37) | CTSSTRPV1ALDH1A2ALDH1A3PDE10A | |
| SCHEMBL4977191 | 0.90 | CTSS (0.39) | CTSSTRPV1ALDH1A2ALDH1A3PDE10A | |
| SCHEMBL4426575 | 0.88 | CTSS (0.36) | CTSSTRPV1ALDH1A2ALDH1A3PDE10A | |
| SCHEMBL4427544 | 0.87 | DRD1 (0.44) | DRD1DRD5 | |
| SCHEMBL4978894 | 0.87 | DRD1 (0.44) | DRD1DRD5 | |
| SCHEMBL4427546 | 0.87 | DRD1 (0.44) | DRD1DRD5 | |
| SCHEMBL4428884 | 0.80 | CTSS (0.38) | CTSSTRPV1ALDH1A2ALDH1A3PDE10A | |
| SCHEMBL4286790 | 0.78 | CTSS (0.38) | CTSSTRPV1ALDH1A2ALDH1A3PDE10A | |
| SCHEMBL4978987 | 0.78 | SMN1; SMN2 (0.37) | CTSSCTSK | |
| SCHEMBL4521064 | 0.78 | HKDC1 (0.40) | CTSSALDH1A2ALDH1A3PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061470-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | Neurogen Corporation (US) | 2009-05-27 | — | — | EP | claimed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | claimed |
| WO-2008024433-A2 | HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | NEUROGEN CORPORATION (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090845-A1 | Haloalkyl-substituted pyrimidinone derivatives | PIGS, GPR174, GPR17 | CTSS 1447/4885TRPV1 159/4885ALDH1A2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.